Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial

Abstract The antiangiogenic agent apatinib has been shown to clinically improve responses to immune checkpoint inhibitors in several cancer types. Patients with N3 nasopharyngeal carcinoma have a high risk of distant metastasis, however, if the addition of immunotherapy to standard treatment could i...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Hu Liang, Yao-Fei Jiang, Guo-Ying Liu, Lin Wang, Jian-Wei Wang, Nian Lu, Wei-Xiong Xia, Liang-Ru Ke, Yan-Fang Ye, Jin-Lin Duan, Wei-Xin Bei, Shu-Hui Dong, Wang-Zhong Li, Li-Ting Liu, Chong Zhao, Changqing Xie, Yan-Qun Xiang
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Nature Portfolio 2024-02-01
Rangatū:	Nature Communications
Urunga tuihono:	https://doi.org/10.1038/s41467-024-45126-0
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!